Section Arrow
CGON.NASDAQ
- CG Oncology
Quotes are at least 15-min delayed:2025/07/17 07:43 EDT
Pre Market
Last
 26.08
0 (0.00%)
Bid
24.5
Ask
26.6
High 26.08 
Low 26.08 
Volume 25 
Regular Hours
Last
 26.08
+1.13 (+4.53%)
Day High 
26.13 
Prev. Close
24.95 
1-M High
27.56 
Volume 
628.13K 
Bid
24.5
Ask
26.6
Day Low
24.7 
Open
24.7 
1-M Low
24.86 
Market Cap 
1.90B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 26.39 
20-SMA 26.15 
50-SMA 25.89 
52-W High 40.47 
52-W Low 14.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.50/-1.54
Enterprise Value
1.90B
Balance Sheet
Book Value Per Share
9.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.14M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APMAptorum Group Limited1.94+0.9702+100.04%2.77PE
Pre Market 1.77 -0.17 -8.76%
TNFATNF Pharmaceuticals Inc.0.109+0.0028+2.64%-- 
Pre Market 0.102 -0.007 -6.42%
NCNANuCana plc0.0502--0.000%-- 
Pre Market 0.0485 -0.0017 -3.39%
BRNSBarinthus Biotherapeutics plc1.42+0.4+39.22%-- 
Pre Market 1.36 -0.06 -4.23%
WINTWindtree Therapeutics Inc.0.9+0.0714+8.62%0.84PE
Pre Market 1.29 +0.39 +43.33%
Quotes are at least 15-min delayed:2025/07/17 07:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.